VirginiaBio · Jul 2026
Event listing for a talk by Chetan Mishra about screening AI coworkers and how Rhizome resolves regulatory strategy and intelligence tasks for life sciences teams.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Rhizome AI is a Y Combinator W26 startup building Rhizome Ask, an AI regulatory coworker for life sciences that answers FDA/EMA and other health-authority questions with cited, hallucination-free research. It targets biotech, pharma, medtech, and regulatory teams, and the public record suggests a very small, remote-first company with 6-figure ARR and a seat/subscription SaaS model.
Primary product
Rhizome Ask — a cited, hallucination-free regulatory agent / AI regulatory coworker for life sciences
Founded
2025
Headquarters
New York, New York, United States
Team size
1-10
Work style
Remote
Industry
Technology, Information and Internet
Sub-industry
Life sciences regulatory intelligence / AI regulatory assistant
0 jobs at Rhizome AI
Check back later for new openings
Offices
Business model
Stage
pre-seed
Total raised
$585K
Latest round
Convertible Note · Jan 2026
Latest amount
$500K
Jan 2026 · Y Combinator
Nov 2025
Leadership
Founder & CEO
Investors
Small remote team with a written-first/async style, high ownership expectations, willingness to travel for periodic offsites, and a strong emphasis on reliability while using AI heavily in engineering work.
Work style
Remote
Compensation
A public hiring post advertised a Founding Full Stack AI Engineer at $60K-$120K salary plus 0.50%–2.00% equity. The company also signals a lean, high-ownership startup environment rather than a broad public compensation philosophy.
Pricing
Freemium SaaS with a $0/mo free tier, $400/mo project tier, $4,000/yr professional tier, $30,000/yr business tier, and custom enterprise pricing
Differentiators
Technology
Customers
Competitors
Estimated revenue
6 figures ARR
Estimated monthly visits
4.7K
Traffic estimate as of Jul 2026
VirginiaBio · Jul 2026
Event listing for a talk by Chetan Mishra about screening AI coworkers and how Rhizome resolves regulatory strategy and intelligence tasks for life sciences teams.
Cure · Jun 2026
Member spotlight on Rhizome AI’s founder describing the product as fast, reliable regulatory intelligence for biotechs and medtech companies, with pricing and customer-use cases discussed.
Center for Data Innovation · Feb 2026
Interview with Chetan Mishra describing Rhizome AI as an LLM/chatbot for life sciences, its use of public health-authority and clinical-trial data, and its proprietary retrieval/validation architecture.
Y Combinator · Jan 2026
YC launch post introducing Rhizome AI and Rhizome Ask as a citation-backed regulatory agent for life sciences; it emphasizes hallucination-free answers, up to 1,000 source documents per question, and the founder’s background.